Compare Stocks: ALNY, REGN, MRNA, and NTRA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$219.72 -5.0%	$241.38	$197.81 ▼ $495.55	$29.40B	0.28	1.31 million shs	1.66 million shs
MRNA Moderna	$190.01 +0.6%	$125.46	$22.28 ▼ $208.90	$75.86B	1.09	14.04 million shs	10.27 million shs
NTRA Natera	$410.35 +0.5%	$332.39	$160.59 ▼ $427.47	$59.15B	1.5	1.57 million shs	2.16 million shs
REGN Regeneron Pharmaceuticals	$735.20 +0.1%	$788.30	$541.00 ▼ $859.34	$75.69B	0.16	724,579 shs	613,942 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	-4.96%	-14.16%	-17.83%	-29.75%	-52.30%
MRNA Moderna	+0.57%	-4.46%	+25.99%	+138.23%	+588.44%
NTRA Natera	+0.46%	-0.54%	+26.20%	+46.91%	+153.91%
REGN Regeneron Pharmaceuticals	+0.05%	-6.71%	-13.71%	+12.37%	+22.55%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$219.72 -5.0%	$241.38	$197.81 ▼ $495.55	$29.40B	0.28	1.31 million shs	1.66 million shs
MRNA Moderna	$190.01 +0.6%	$125.46	$22.28 ▼ $208.90	$75.86B	1.09	14.04 million shs	10.27 million shs
NTRA Natera	$410.35 +0.5%	$332.39	$160.59 ▼ $427.47	$59.15B	1.5	1.57 million shs	2.16 million shs
REGN Regeneron Pharmaceuticals	$735.20 +0.1%	$788.30	$541.00 ▼ $859.34	$75.69B	0.16	724,579 shs	613,942 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	-4.96%	-14.16%	-17.83%	-29.75%	-52.30%
MRNA Moderna	+0.57%	-4.46%	+25.99%	+138.23%	+588.44%
NTRA Natera	+0.46%	-0.54%	+26.20%	+46.91%	+153.91%
REGN Regeneron Pharmaceuticals	+0.05%	-6.71%	-13.71%	+12.37%	+22.55%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALNY Alnylam Pharmaceuticals	2.83	Moderate Buy	$366.90	66.99% Upside
MRNA Moderna	2.08	Hold	$77.83	-59.04% Downside
NTRA Natera	2.83	Moderate Buy	$341.55	-16.77% Downside
REGN Regeneron Pharmaceuticals	2.69	Moderate Buy	$809.50	10.11% Upside

Current Analyst Ratings Breakdown

Latest ALNY, REGN, MRNA, and NTRA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/1/2026	NTRA Natera	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$360.00 ➝ $475.00
10/1/2026	REGN Regeneron Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$870.00 ➝ $930.00
10/1/2026	REGN Regeneron Pharmaceuticals	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Buy	$850.00
9/30/2026	ALNY Alnylam Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
9/30/2026	MRNA Moderna	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Neutral ➝ Sell	$60.00 ➝ $80.00
9/30/2026	ALNY Alnylam Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$375.00 ➝ $369.00
9/29/2026	REGN Regeneron Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sector Perform	$737.00
9/28/2026	REGN Regeneron Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
9/25/2026	NTRA Natera	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$350.00 ➝ $460.00
9/25/2026	MRNA Moderna	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Perform
9/23/2026	MRNA Moderna	Singular Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold

(Data available from 10/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNY Alnylam Pharmaceuticals	$3.71B	7.92	$2.80 per share	78.58	$5.97 per share	36.80
MRNA Moderna	$1.94B	39.02	N/A	N/A	$22.14 per share	8.58
NTRA Natera	$2.71B	21.85	N/A	N/A	$12.38 per share	33.15
REGN Regeneron Pharmaceuticals	$14.34B	5.28	$41.99 per share	17.51	$295.66 per share	2.49

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNY Alnylam Pharmaceuticals	$313.75M	$5.38	40.84	22.65	N/A	15.26%	84.93%	14.30%	10/29/2026 (Estimated)
MRNA Moderna	-$2.82B	-$7.99	N/A	N/A	N/A	-141.43%	-28.30%	-19.39%	11/5/2026 (Estimated)
NTRA Natera	-$208.16M	-$1.36	N/A	41,035.00	N/A	-7.11%	-11.38%	-7.87%	11/5/2026 (Estimated)
REGN Regeneron Pharmaceuticals	$4.50B	$40.46	18.17	14.11	1.41	27.86%	13.47%	10.34%	10/30/2026 (Estimated)

Latest ALNY, REGN, MRNA, and NTRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
10/30/2026	Q3 2026	REGN Regeneron Pharmaceuticals	$15.99	N/A	N/A	N/A	$4.54 billion	N/A
10/29/2026	Q3 2026	ALNY Alnylam Pharmaceuticals	$1.77	N/A	N/A	N/A	$1.43 billion	N/A
8/6/2026	Q2 2026	NTRA Natera	-$0.4939	-$0.47	+$0.0239	-$0.47	$661.24 million	$752.75 million
7/31/2026	Q2 2026	MRNA Moderna	-$2.03	-$1.97	+$0.06	-$1.97	$102.93 million	$145.00 million
7/30/2026	Q2 2026	ALNY Alnylam Pharmaceuticals	$1.63	$1.84	+$0.21	$1.21	$1.32 billion	$1.29 billion
7/30/2026	Q2 2026	REGN Regeneron Pharmaceuticals	$10.16	$14.29	+$4.13	$12.23	$3.82 billion	$4.29 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNY Alnylam Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
NTRA Natera	N/A	N/A	N/A	N/A	N/A
REGN Regeneron Pharmaceuticals	$3.76	0.51%	N/A	9.29%	N/A

Latest ALNY, REGN, MRNA, and NTRA Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/30/2026	REGN Regeneron Pharmaceuticals	quarterly	$0.94	0.46%	8/18/2026	8/18/2026	8/31/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNY Alnylam Pharmaceuticals	0.75	3.05	2.99
MRNA Moderna	0.09	2.29	2.18
NTRA Natera	N/A	3.00	2.85
REGN Regeneron Pharmaceuticals	0.06	3.34	2.78

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALNY Alnylam Pharmaceuticals	92.97%
MRNA Moderna	75.33%
NTRA Natera	99.90%
REGN Regeneron Pharmaceuticals	83.31%

Insider Ownership

Company	Insider Ownership
ALNY Alnylam Pharmaceuticals	0.86%
MRNA Moderna	10.80%
NTRA Natera	5.05%
REGN Regeneron Pharmaceuticals	6.97%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNY Alnylam Pharmaceuticals	2,770	133.81 million	132.66 million	Optionable
MRNA Moderna	4,700	399.24 million	356.12 million	Optionable
NTRA Natera	6,140	144.14 million	136.87 million	Optionable
REGN Regeneron Pharmaceuticals	15,410	102.96 million	95.78 million	Optionable

ALNY, REGN, MRNA, and NTRA Headlines

Recent News About These Companies

Jefferies Financial Group Forecasts Strong Price Appreciation for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock

October 3 at 2:36 AM | americanbankingnews.com

Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Rating Upgraded by Argus

October 3 at 1:48 AM | americanbankingnews.com

Vertex (VRTX) or Regeneron (REGN)? Two Biotech Moats, Two Very Different Bets

October 2 at 10:51 PM | insidermonkey.com

Sanofi pays Regeneron up to $8B to expand immunology alliance

October 2 at 3:52 PM | qz.comQ

Sanofi, Regeneron Expand Immunology Alliance With New Antibodies

October 2 at 3:52 PM | finance.yahoo.com

Sanofi, Regeneron Expand Immunology Alliance With New Antibodies

October 2 at 10:46 AM | zacks.com

Regeneron reports 73% response rate for ubamatamab in ovarian cancer

October 1 at 5:32 PM | streetinsider.com

Regeneron's Ubamatamab, Trevogrumab Show Strong Results In Cancer And Obesity Studies

October 1 at 5:32 PM | rttnews.com

Regeneron drops after early-stage trial data for ovarian cancer therapy

October 1 at 5:32 PM | seekingalpha.com

Regeneron Pharmaceuticals, Inc. (REGN) Discusses Expanded Collaboration on Next-Generation Long-Acting Immunology Antibodies Transcript

October 1 at 4:00 PM | seekingalpha.com

Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $930.00

October 1 at 2:47 PM | marketbeat.com

Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss

October 1 at 12:30 PM | finance.yahoo.com

Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)

October 1 at 12:30 PM | finance.yahoo.com

Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)

October 1 at 11:35 AM | globenewswire.com

Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss

October 1 at 11:30 AM | globenewswire.com

Regeneron, Sanofi Expand Alliance in Deal Worth Up to $8 Billion

October 1 at 11:01 AM | marketbeat.com

Regeneron Pharmaceuticals, Inc. (REGN) Discusses Expanded Collaboration on Next-Generation Long-Acting Immunology Antibodies - Slideshow

October 1 at 10:51 AM | seekingalpha.com

Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to Win

October 1 at 10:50 AM | zacks.com

Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at Argus

October 1 at 8:41 AM | marketbeat.com

Regeneron and Sanofi expand alliance with $1 Bln upfront deal

October 1 at 7:30 AM | streetinsider.com

Sanofi gains after expanding Regeneron partnership with $8 billion deal

October 1 at 7:30 AM | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ALNY, REGN, MRNA, and NTRA Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

$219.72 -11.46 (-4.96%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$220.10 +0.38 (+0.17%)

As of 10/2/2026 07:49 PM Eastern

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Moderna NASDAQ:MRNA

$190.01 +1.07 (+0.57%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$189.57 -0.44 (-0.23%)

As of 10/2/2026 07:59 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Natera NASDAQ:NTRA

$410.35 +1.88 (+0.46%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$411.78 +1.43 (+0.35%)

As of 10/2/2026 07:55 PM Eastern

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Regeneron Pharmaceuticals NASDAQ:REGN

$735.20 +0.39 (+0.05%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$737.44 +2.24 (+0.30%)

As of 10/2/2026 08:00 PM Eastern

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALNY, REGN, MRNA, and NTRA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALNY, REGN, MRNA, and NTRA Earnings

Compare Dividends

Latest ALNY, REGN, MRNA, and NTRA Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALNY, REGN, MRNA, and NTRA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ALNY, REGN, MRNA, and NTRA Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

Moderna NASDAQ:MRNA

Natera NASDAQ:NTRA

Regeneron Pharmaceuticals NASDAQ:REGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools